MXCT Maxcyte (MXCT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Services-commercial physical & biological research · CIK 0001287098
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
78
13F, latest reported quarter
What the filings say about MXCT
Activist stakes (13D), 180 days
3 filings
Largest: 6.1% of the class
Maxcyte insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for MAXCYTE, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Aug 13, 2025.
- The trade is 6.7% of the 151,669 shares held after it.
- No other insider sold within 30 days.
- 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Swirsky Douglas J sold about $8.3K of MXCT on Mar 17, 2026; 78 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 18, 2025.
- The trade is 30.9% of the 161,811 shares held after it.
- 4 other insiders bought within 30 days.
- 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Swirsky Douglas J bought about $64.5K of MXCT on Aug 13, 2025, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days and 78 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (2 buys, 3 sales), the last on Jun 10, 2024.
- -20.7% median (-20.7% mean) 90-day return after 2 previous buys.
- The trade is 42.9% of the 175,000 shares held after it.
- 4 other insiders bought within 30 days.
- 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Masoud Maher bought about $102.8K of MXCT on Aug 13, 2025, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days and 78 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Nov 1, 2024.
- The trade is 25.1% of the 398,328 shares held after it.
- 4 other insiders bought within 30 days.
- 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Erck Stanley C bought about $137.0K of MXCT on Aug 13, 2025, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days and 78 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 29, 2023.
- -20.5% median (-20.5% mean) 90-day return after 2 previous buys.
- The trade is 34.7% of the 230,577 shares held after it.
- 4 other insiders bought within 30 days.
- 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DOUGLAS RICHARD bought about $111.2K of MXCT on Aug 13, 2025, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days and 78 funds added in the latest 13F quarter.106 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
78 funds bought in last quarter
more than 59% of Pharma & Biotech
Revenue
-5.7% year over year
below 62% of Pharma & Biotech
Margin
-213.0% net margin
below 67% of Pharma & Biotech
Buybacks
$1.5M repurchased, FY to 2026-06-30
below 88% of Pharma & Biotech
Short interest
1.2% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
below 72% of Pharma & Biotech
The situation: each line is one rule over one dataset
Liontrust Investment Partners LLP disclosed a 5%+ stake (5.0%) in the last six months.
What changed in the last 30 days
Oct 15Liontrust Investment Partners LLP filed a 13D for 5.0%
Watch MXCT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-6.8%12M
Insider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MXCT: institutional holders (13F)
13F holdings, latest reported quarter
8,200,000 sh
$10.1M
5,043,356 sh
$6.2M
4,031,284 sh
$5.0M
3,694,049 sh
$4.5M
3,370,689 sh
$4.1M
Congress trades in MXCT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Liontrust Investment Partners LLP
Activist 13D · 2026-10-15
5.0%
RIVER GLOBAL INVESTORS LLP
Activist 13D · 2026-08-04
0.8%
RIVER GLOBAL INVESTORS LLP
Activist 13D · 2026-05-14
6.1%
MXCT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MXCT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$114.6K position · as of 2026-05-31
0.6%
Inception Portfolio
$427.3K position · as of 2026-06-30
0.2%
EQ/Morgan Stanley Small Cap Growth Portfolio
$260.7K position · as of 2026-06-30
0.1%
NVIT Small Cap Value Fund
$45.7K position · as of 2026-06-30
0.0%
Multi-Manager Small Cap Equity Strategies Fund
$174.3K position · as of 2026-05-31
0.0%
NVIT Multi-Manager Small Company Fund
$53.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 78 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MXCT financials
Revenue growth
-5.7%
XBRL, annual
Net margin
-213.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$31.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MXCT
| FY Dec 2025 | $33.0M |
| FY Dec 2024 | $38.6M |
| FY Dec 2023 | $41.3M |
| FY Dec 2022 | $44.3M |
| FY Dec 2021 | $33.9M |
| Jun 2026 | $7.3M |
| Mar 2026 | $9.7M |
| Dec 2025 | $7.3M |
| Sep 2025 | $6.8M |
| Jun 2025 | $8.5M |
| Mar 2025 | $10.4M |
| Dec 2024 | $8.7M |
| Sep 2024 | $8.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-114.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MXCT
| FY Dec 2025 | -135.1% |
| FY Dec 2024 | -106.3% |
| FY Dec 2023 | -91.8% |
| FY Dec 2022 | -53.3% |
| FY Dec 2021 | -56.3% |
| Jun 2026 | -122.0% |
| Mar 2026 | -49.2% |
| Dec 2025 | -131.5% |
| Sep 2025 | -181.8% |
| Jun 2025 | -145.3% |
| Mar 2025 | -98.8% |
| Dec 2024 | -121.9% |
| Sep 2024 | -141.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$23.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MXCT
| FY Dec 2025 | -$36.2M |
| FY Dec 2024 | -$29.3M |
| FY Dec 2023 | -$25.4M |
| FY Dec 2022 | -$33.3M |
| FY Dec 2021 | -$14.5M |
| Jun 2026 | -$4.7M |
| Mar 2026 | -$8.2M |
| Dec 2025 | -$2.9M |
| Sep 2025 | -$7.8M |
| Jun 2025 | -$10.4M |
| Mar 2025 | -$15.1M |
| Dec 2024 | -$8.0M |
| Sep 2024 | -$4.8M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity MXCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt MXCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-20.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MXCT
| FY Dec 2025 | -23.6% |
| FY Dec 2024 | -18.7% |
| FY Dec 2023 | -15.6% |
| FY Dec 2022 | -9.1% |
| FY Dec 2021 | -12.9% |
| Jun 2026 | -20.4% |
| Mar 2026 | -21.3% |
| Dec 2025 | -23.6% |
| Sep 2025 | -23.2% |
| Jun 2025 | -21.7% |
| Mar 2025 | -19.6% |
| Dec 2024 | -18.7% |
| Sep 2024 | -16.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-17.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MXCT
| FY Dec 2025 | -20.2% |
| FY Dec 2024 | -16.2% |
| FY Dec 2023 | -13.7% |
| FY Dec 2022 | -8.3% |
| FY Dec 2021 | -11.4% |
| Jun 2026 | -17.6% |
| Mar 2026 | -18.4% |
| Dec 2025 | -20.2% |
| Sep 2025 | -19.7% |
| Jun 2025 | -19.0% |
| Mar 2025 | -17.1% |
| Dec 2024 | -16.2% |
| Sep 2024 | -13.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital MXCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-21.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MXCT
| FY Dec 2025 | -25.2% |
| FY Dec 2024 | -21.6% |
| FY Dec 2023 | -18.5% |
| FY Dec 2022 | -10.1% |
| FY Dec 2021 | -11.8% |
| Jun 2026 | -21.8% |
| Mar 2026 | -22.8% |
| Dec 2025 | -25.2% |
| Sep 2025 | -25.0% |
| Jun 2025 | -23.9% |
| Mar 2025 | -22.2% |
| Dec 2024 | -21.6% |
| Sep 2024 | -19.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MXCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value MXCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-15.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield MXCT
| FY Dec 2025 | -21.9% |
| FY Dec 2024 | -6.7% |
| FY Dec 2023 | -5.2% |
| FY Dec 2022 | -6.0% |
| FY Dec 2021 | -1.4% |
| Jun 2026 | -17.9% |
| Mar 2026 | -39.1% |
| Dec 2025 | -21.9% |
| Sep 2025 | -24.5% |
| Jun 2025 | -16.5% |
| Mar 2025 | -11.4% |
| Dec 2024 | -6.7% |
| Sep 2024 | -5.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MXCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M |
| Gross profit | $26.8M | $31.5M | $36.5M | $39.2M |
| Operating income | -$51.9M | -$51.2M | -$48.3M | -$27.4M |
| Net income | -$44.6M | -$41.1M | -$37.9M | -$23.6M |
| EPS (diluted) | -0.42 | -0.39 | -0.37 | -0.23 |
| Operating cash flow | -$34.4M | -$27.6M | -$21.7M | -$14.8M |
| Cash | $20.1M | $27.9M | $46.5M | $11.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
MXCT Stock Sonar score 4/7 axes
Find similar shapesCompareMXCT ranks highest on risk and compliance (81st percentile) and profitability (71st), and lowest on institutional and government (59th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MXCT filings, in plain words
Read the full summary
3 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 6.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
